Is Genenta Science S.p.A. (GNTA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 62.8% / 30% | 7.2% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 62.8% / 33% | 7.2% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 85.4% / 33% | 9.8% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 62.8% / 33% | 7.2% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 85.4% / 33% | 9.8% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -60.1% | |
| Return on Assets (ROA) | -26.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$6M |
| Free Cash Flow | -$6M |
| Debt-to-Equity | 62.4 |
| Current Ratio | 13.2 |
| Total Assets | $15M |
Price & Trading
| Last Close | $0.83 |
| 50-Day MA | $0.96 |
| 200-Day MA | $2.40 |
| Avg Volume | 1.1M |
| Beta | 0.6 |
|
52-Week Range
$0.59
| |
About Genenta Science S.p.A. (GNTA)
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. The company was incorporated in 2014 and is headquartered in Milan, Italy.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Genenta Science S.p.A. (GNTA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Genenta Science S.p.A. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Genenta Science S.p.A.'s debt ratio?
Genenta Science S.p.A.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Genenta Science S.p.A.'s key financial metrics?
Genenta Science S.p.A. has a market capitalization of $17M. Return on equity stands at -60.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.